Company Encyclopedia
View More
name
Cochlear Limited
COH.AU
News
View More

Cochlear Limited’s Innovative Study on Speech Perception Using Mobile App

Cochlear Limited is conducting a study titled ‘A Prospective, Repeated-measures Investigation to Validate Digital Speech Perception Endpoints in Adult Cochlear Implant Recipients Using the Mobile Research App.’ The study aims to validate speech perception assessments for adults with cochlear implants using a mobile app, enhancing understanding and management of hearing loss. It tests the Mobile Research App (MRA) for flexible testing. The study began on October 19, 2023, and is recruiting participants, with completion expected by April 27, 2025. This innovation may positively impact Cochlear Limited’s stock performance and investor sentiment.

Tip Ranks·
US
CHEOY
+0.37%
Tip Ranks·
US
CHEOY
+0.37%

Cochlear Limited Announces Franked Ordinary Dividend for the Six Months Ended June 30, 2025, Payable on October 13, 2025

Cochlear Limited announced franked ordinary dividend of AUD 2.15000000 per share for the six months ended June 30, 2025, payable on October 13, 2025. Record Date is September 19, 2025. Ex Date is September 18, 2025.

marketscreener·
US
CHEOY
+0.37%
marketscreener·
US
CHEOY
+0.37%

Cochlear Limited Reports Growth and Innovation in 2025

Cochlear Limited (CHEOF) reported its Q4 earnings, showcasing a 4% increase in sales revenue to $2,356 million and a 1% rise in underlying net profit to $392 million for FY25. The company launched the Nucleus Nexa System, the first smart cochlear implant with upgradeable firmware, and invested $292 million in R&D. With over 60% market share, Cochlear aims to help over 60,000 people with hearing implants in FY26, projecting an 11-17% increase in net profit. The company emphasizes growth through innovation and sustainability initiatives.

Tip Ranks·
US
CHEOY
+0.37%
Tip Ranks·
US
CHEOY
+0.37%

Cochlear Secures US FDA Approval for Smart Cochlear Implant System

Cochlear said it received regulatory approval for the Nucleus Nexa System, Nucleus Kanso 3, and Kanso 3 Nexa sound processors from the US Food and Drug Administration (FDA), according to a Tuesday Australian bourse filing. The firm expects to launch the new products in the US by the end of the first quarter of fiscal year 2026.

Trading View·
US
CHEOY
+0.37%
Trading View·
US
CHEOY
+0.37%

Cochlear Launches World's First and Only Smart Cochlear Implant System | CHEOY Stock News

Cochlear Limited has received FDA approval for the Cochlear™ Nucleus® Nexa™ System, the world's first smart cochlear implant system. This innovative system features upgradeable firmware, allowing recipients to access future technology updates. The Nucleus 8 Nexa Sound Processor is the smallest and lightest on the market, with all-day battery life. The system includes internal memory for secure storage of personalized hearing settings and supports upgrades for legacy Nucleus Systems. This advancement aims to enhance the hearing experience for cochlear implant users.

StockTitan·
US
CHEOY
+0.37%
StockTitan·
US
CHEOY
+0.37%